Global Pharma and Biotech Clinical Stage Partnering Terms

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
25
Global Pharma and Biotech Clinical Stage Partnering Terms and Agreements Report 2018

Dublin, Feb. 13, 2019 (GLOBE NEWSWIRE) -- The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018" report has been added to ResearchAndMarkets.com's offering. The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012- 2018 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of over 2,000 clinical stage partnering deals announced since 2012 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others. The report also includes numerous tables and figures that illustrate the trends and activities in clinical stage partnering and deal making since 2012. In addition, a comprehensive appendix of all clinical stage deals since 2012 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Why do companies partner clinical stage compounds? 2.1. Introduction 2.2. The role of clinical stage partnering 2.2.1. In-licensing at clinical stage 2.2.2. Out-licensing at clinical stage 2.3. Difference between phase I, II and III stage deals 2.4. Reasons for entering into clinical stage partnering deals 2.4.1. Licensors reasons for entering clinical stage deals 2.4.2. Licensees reasons for entering clinical stage deals 2.5. The future of clinical stage partnering deals Chapter 3 - Clinical stage deal strategies and structure 3.1. Introduction 3.2. At what stage do companies partner? 3.2.1. Partnering early in pharmaceutical/biotech 3.2.1.1. Discovery and preclinical stage partnering case studies 3.2.1.1.a. Case study: LEO Pharma - 4SC 3.2.1.1.b. Case study: Heptares Therapeutics - Cubist 3.2.1.1.c. Case study: Incyte - Agenus Bio 3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec 3.2.2. Partnering later in pharmaceutical/biotech 3.2.2.1. Clinical stage partnering case studies 3.2.2.1.a. Case study: Servier - GeNeuro 3.2.2.1.b. Case study: Teva - Xenon Pharmaceuticals 3.2.2.1.c. Case study: AstraZeneca - Ardelyx 3.2.2.1.d. Case study: Baxter - Onconova Therapeutics 3.3. Early and later stage partnering - a risk/cost comparison 3.4. What do companies spend on clinical stage partnering? 3.5. Pure versus multi-component partnering deals 3.6. Pure licensing agreement structure 3.6.1. Example pure licensing agreements 3.6.1.a. Case study : Argos Therapeutics - Medinet 3.6.1.b. Case study : Pfizer - GlycoMimetics 3.7. Multicomponent clinical stage partnering agreements 3.7.1. Example multicomponent clinical stage clauses 3.7.1.a. Case study: Gilead Sciences - GlobeImmune Chapter 4 - Clinical stage partnering payment strategies 4.1. Introduction 4.2. Clinical stage payment strategies 4.3. Payment options 4.3.1. Headline values 4.3.2. Upfront payments 4.3.2.1. Conditionality of upfront payments 4.3.3. Loans 4.3.4. Convertible loans 4.3.5. Equity 4.3.6. R&D funding 4.3.7. Licensing fees 4.3.8. Milestone payments 4.3.9. Royalty payments 4.3.9.1. Issues affecting royalty rates 4.3.9.2. Royalties on combination products 4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech 4.3.9.3. Guaranteed minimum/maximum annual payments 4.3.9.4. Royalty stacking 4.3.9.5. Royalties and supply/purchase contracts 4.3.10. Quids 4.3.11. Option payments Chapter 5 - Trends in clinical stage deal making 5.1. Introduction 5.2. Clinical stage partnering over the years 5.2.1. Trends in phase I deals since 2012 5.2.1.1. Attributes of phase I deals 5.2.2. Trends in phase II deals since 2012 5.2.2.2. Attributes of phase II deals 5.2.3. Trends in phase III deals since 2012 5.2.3.1. Attributes of phase III deals 5.3. Clinical stage partnering by deal type 5.4. Clinical stage partnering by disease type 5.5. Partnering by clinical stage technology type 5.6. Clinical stage partnering by most active company since 2012 Chapter 6 - Payment terms for clinical stage partnering 6.1. Introduction 6.2. Guidelines for clinical stage payment terms 6.2.1. Upfront payments 6.2.2. Milestone payments 6.2.3. Royalty payments 6.3. Clinical stage payment terms - deal data analysis 6.3.1. Public data 6.3.2. Survey data 6.4. Payment terms analysis 6.4.1. Clinical stage partnering headline values 6.4.2. Clinical stage deal upfront payments 6.4.3. Clinical stage deal milestone payments 6.4.4. Clinical stage royalty rates 6.5 Clinical stage median financials 6.5.1. Clinical stage headline value 6.5.2. Clinical stage upfront value 6.5.3. Clinical stage milestone value 6.5.4. Clinical stage royalty value Chapter 7 - Leading clinical stage deals 7.1. Introduction 7.2. Top clinical stage deals by value Chapter 8 - Top 50 most active clinical stage dealmakers 8.1. Introduction 8.2. Top 50 most active clinical stage dealmakers Chapter 9 - Clinical stage partnering contracts directory 9.1. Introduction 9.2. Clinical stage deals with contracts since 2012 Chapter 10 - Clinical stage deal making by development stage 10.1. Introduction 10.2. Deals by clinical stage Phase I Phase II Phase III Regulatory Formulation Appendices Appendix 1 - Clinical stage dealmaking by companies A-Z Appendix 2 - Clinical stage dealmaking by industry sector Appendix 3 - Clinical stage dealmaking by stage of development Appendix 4 - Clinical stage dealmaking by therapy area Appendix 5 - Clinical stage dealmaking by technology type For more information about this report visit https://www.researchandmarkets.com/research/s...a_and?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Biotechnology, Clinical Trials

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veterans Find a Haven in Home Helpers® Franchise

Updated Category News Views 70

Veterans Thriving at Home Helpers® Tossing out a warm welcome to fresh horizons post-military, Home Helpers® Home Care is serving up more than just compassionate care—it’s become a bonafide haven for veterans diving into the world of franchising. This isn’t just an indie pat on the back; according to the latest scoop from Franchise Business Review, Home Helpers®...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 86

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 89

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 70

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 122

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Investors, Portillo's Fraud Claims Demand Your Attention

Updated Category News Views 0

Portillo's Investors Caught in a Tough Spot Ah, Portillo's. You thought those hot dogs were the only spicy thing you're biting into? Try these allegations on for size. Investors are biting back with a securities fraud lawsuit, and the details are saltier than a bucket of fries. The folks who held PTLO shares between September 19, 2023, and May 4, 2026, are in the...

Continue Reading
Better Life Science: Revolutionizing At-Home STI Testing

Updated Category News Views 115

Paving a New Path for STI Testing Accessibility The landscape of STI testing is undergoing a significant shift, and Better Life Science is at the helm with their innovative STD Hero at-home testing service. With a splash in the latest AVN report, they're turning heads in both the clinical world and in mainstream society. This ain't just about checking boxes in health...

Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 107

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 65

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading

Top 5 Most Recently Viewed Articles

Ethan Allen Launches Stylish Design Center in Colorado Springs

Updated Category News Views 229

Introducing the New Ethan Allen Design Center Ethan Allen has proudly opened its latest Design Center in Colorado Springs, situated in the vibrant University Village Shopping Center. This newly constructed space features a beautiful gallery showroom, along with workspaces designed for collaboration between designers and clients. This new center is the fourth for Ethan...

Continue Reading
Understanding Ark Invest's Strategic Moves with AI Leaders

Updated Category News Views 349

Ark Invest's Bold Moves in the AI Sector Cathie Wood, the impactful leader of Ark Invest, continues to make headlines with her investment decisions. Recently, Ark made some noteworthy trades involving Baidu Inc. (NASDAQ: BIDU), Alibaba Group Holding Ltd. (NYSE: BABA), and Brera Holdings PLC (NASDAQ: BREA). These investments spotlight Ark's belief in companies championing...

Continue Reading
Broadcom's Future: Analyst Ratings Fuel Optimism for 2026

Updated Category News Views 287

Broadcom's Impressive Rally and Analysts' Confidence Recently, semiconductor giant Broadcom saw a remarkable rebound, achieving a staggering total return of 51%. This performance stands in sharp contrast to the previous year's underwhelming conclusion. Investors have taken a keen interest in the company, especially as it consistently outpaces the S&P 500’s return, which...

Continue Reading
Novavax's Earnings Preview: What Investors Should Expect

Updated Category News Views 160

Key Insights Before Novavax's Earnings Report Novavax (NASDAQ: NVAX) is set to announce its quarterly earnings soon, and anticipation is building among investors. This overview highlights essential factors for those interested in the upcoming earnings report. Expected Earnings Performance Analysts predict that Novavax will report an earnings per share (EPS) of...

Continue Reading
Bank7 Corp. Reports Impressive Q3 2024 Earnings Results

Updated Category News Views 130

Bank7 Corp. Achieves Record Earnings for Q3 2024 Bank7 Corp. (NASDAQ: BSVN), the parent company of Bank7, has announced outstanding financial results for the third quarter of 2024. In a recent statement, President and CEO Thomas L. Travis remarked, "We are pleased to announce another record quarter of net income and EPS. Our properly matched balance sheet, disciplined...

Continue Reading